CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
原代 T 细胞中基于 CRISPR 的基因编辑挑战
英文原题：Challenges of CRISPR-Based Gene Editing in Primary T Cells.
查看英文原题
Challenges of CRISPR-Based Gene Editing in Primary T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
适应性T细胞免疫治疗为成功治疗白血病及其他癌症带来巨大希望。近期研究也显示，它可有效治疗免疫抑制患者的慢性病毒感染。用于免疫治疗的自体或异基因T细胞通常经过基因改造，以表达新的T细胞受体或嵌合抗原受体。CRISPR/Cas系统显著简化了这类细胞的制备，可在基因组特定位点删除或插入新基因。本综述介绍对开展这类基因改造至关重要的近期方法学突破，总结开展相关实验时需考虑的关键问题，并强调这些方法可能存在的陷阱。
展开英文摘要原文
Adaptive T-cell immunotherapy holds great promise for the successful treatment of leukemia, as well as other types of cancers. More recently, it was also shown to be an effective treatment option for chronic virus infections in immunosuppressed patients. Autologous or allogeneic T cells used for immunotherapy are usually genetically modified to express novel T-cell or chimeric antigen receptors.
The production of such cells was significantly simplified with the CRISPR/Cas system, allowing for the deletion or insertion of novel genes at specific locations within the genome. In this review, we describe recent methodological breakthroughs that were important for the conduction of these genetic modifications, summarize crucial points to be considered when conducting such experiments, and highlight the potential pitfalls of these approaches.
论文信息
- 作者
- Rezalotfi A、Fritz L、Förster R、Bošnjak B
- 单位
- Institute of Immunology, Hannover Medical School, 30625 Hannover, Germany.Germany
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2022 Feb 1
- 原文标识
- PubMed 35163611 · DOI 10.3390/ijms23031689
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →